Skip to main content

Table 1 Treatment outcome of AL and AS/AQ at D28.

From: Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: A report from three study sites in sub-Saharan Africa

Study site Drug used Enrolled Parasitaemic patients on D0 N (%) Patients seen at D28 N (%) Crude parasitological failure (%) Geometric mean parasite density D28 (p/μl) PCR adjusted failure rate* PCR adjusted cure rate
Badeku & Ojoku/Ajia Nigeria AL 432 306 (70.8%)
C.I. 67%–75%
184 (60.1%) 77/184 (41.8%)
C.I. 35%–49%
2835 14/154 (9.1%) 90.9%
C.I.
86%–95%
Ejisu-Juaben, Ghana AS/AQ 848 603 (71.1%)
C.I. 68%–74%
205 (34%) 57/205 (27.8%)
C.I. 22%–34%
15080 17/197 (8.6%) 91.4%
C.I.
87%–95%
Bugiri, Uganda AL 460 280 (60.9%)
C.I. 56%–65%
217 (77.5%) 8/217 (3.7%)
C.I. 1.2%–6.2%
N/A 6/216 (2.8%) 97.2%
C.I.
95%–99%
  1. *= Samples that could not be classified by PCR were excluded from the analysis
  2. AL = artemether-lumefantrine
  3. AS/AQ = artesunate-amodiaquine